Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

v3.19.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Condensed Consolidated Statements Of Operations        
Revenues
Operating expenses:        
General and administrative 64,385 101,948 227,153 395,085
Total operating expenses 64,385 101,948 227,153 395,085
Loss from operations (64,385) (101,948) (227,153) (395,085)
Other income (expense):        
Gain (loss) on fair value adjustment - derivatives 112,283 (12,023)
Interest expense (65,193) (48,267) (197,409) (141,114)
Amortization of interest- beneficial conversion feature (4,033) (4,533) (21,500)
Total other income (expense) (69,226) 64,016 (201,942) (174,637)
Loss before provision for income taxes (133,611) (37,932) (429,095) (569,722)
Provision for income tax
Net loss (133,611) (37,932) (429,095) (569,722)
Less: Net loss attributable to noncontrolling interest 769 1,067 2,394 (233)
Net loss attributable to TranBioTec, Inc. $ (132,842) $ (36,865) $ (426,701) $ (569,955)
Net loss per share        
(Basic and fully diluted) $ (0.001) $ (0.000) $ (0.004) $ (0.006)
Weighted average number of common shares outstanding 116,751,078 107,171,429 113,797,952 94,673,333